Resource Summary Report

Generated by NIF on May 20, 2025

Be The Cure

RRID:SCR_003746

Type: Tool

Proper Citation

Be The Cure (RRID:SCR_003746)

Resource Information

URL: http://btcure.eu/

Proper Citation: Be The Cure (RRID:SCR_003746)

Description: Consortium bringing together academic and industry researchers to advance the understanding of disease causing factors and disease progression in Rheumatoid Arthritis (RA), with a focus on accelerating the development of new drugs. The efforts under this consortium aim to develop: (1) animal models; (2) human biobanks, databases and technologies; (3) research network to address critical biologic and clinical questions; (4) community to network patients and companies. The focus will be the development of new diagnostic methods to discover the early forms of RA as well as tools to separate the different forms of RA, where different molecular mechanisms are involved and where different therapies may be required. The ultimate goal for therapeutic development is to identify the disease-causing molecular events early in the disease and then influence immunity and inflammation so that functional deterioration is halted, immunity is re-regulated and the disease is cured. Samples from biobanks will be analysed in vitro and models will be aligned with different variants of human arthritis. In addition, new models will be established using similar molecular pathways as the relevant human arthritis subsets, leading to the understanding of the etiology and early pathology of the disease for a program aimed at early and curative treatment of RA and RA-like diseases. A major focus of these efforts will be to understand and subsequently alter the adaptive immune reactions in patients from a disease-inducing mode into either a protective mode against the disease or become asymptomatic.

Abbreviations: BTCure

Synonyms: Be The Cure For Rheumatoid Arthritis

Resource Type: organization portal, data or information resource, consortium, portal

Keywords: consortium, drug development, biomarker, diagnostic method, drug, immunity,

inflammation

Funding: Innovative Medicines Initiative

Resource Name: Be The Cure

Resource ID: SCR_003746

Alternate IDs: nlx_157979

Record Creation Time: 20220129T080220+0000

Record Last Update: 20250519T203302+0000

Ratings and Alerts

No rating or validation information has been found for Be The Cure.

No alerts have been found for Be The Cure.

Data and Source Information

Source: SciCrunch Registry

Usage and Citation Metrics

We found 5 mentions in open access literature.

Listed below are recent publications. The full list is available at <u>NIF</u>.

Reed E, et al. (2020) Presence of autoantibodies in "seronegative" rheumatoid arthritis associates with classical risk factors and high disease activity. Arthritis research & therapy, 22(1), 170.

Laverty H, et al. (2019) The Innovative Medicines Initiative -10 Years of Public-Private Collaboration. Frontiers in medicine, 6, 275.

Roeleveld DM, et al. (2017) Higher efficacy of anti-IL-6/IL-21 combination therapy compared to monotherapy in the induction phase of Th17-driven experimental arthritis. PloS one, 12(2), e0171757.

Reed E, et al. (2016) Antibodies to carbamylated ?-enolase epitopes in rheumatoid arthritis also bind citrullinated epitopes and are largely indistinct from anti-citrullinated protein

antibodies. Arthritis research & therapy, 18(1), 96.

Hawkins P, et al. (2015) Applying refinement to the use of mice and rats in rheumatoid arthritis research. Inflammopharmacology, 23(4), 131.